Pathway attended last week the Association of Medical Diagnostics Manufacturers’ (AMDM) 16th IVD Regulatory Focus Meeting. The two-day educational conference focused on personalized medicine and highlighted the pending changes in IVD regulation that are being discussed because of recent advancements in molecular and genetic testing.
“There were some excellent discussions on the statistics of diagnostic tests and the formation of the industry,” said David Becker, Ph.D., Pathway’s chief scientific officer. “It was a rewarding opportunity to continue the dialogue with leaders in the field about the possible future layout of regulation within the industry.”
Because of our commitment to bringing high caliber and accurate genetic testing to physicians and their patients, Pathway is dedicated to continuously participating in important events and reporting developments that affect the field of genetic testing. What is halted, hindered or embraced today will inevitably have a lasting effect on succeeding generations.